| Oct 30 |
AbbVie in charts: Humira Q3 revenues of $2.23B plunges 37%, Skyrizi, Rinvoq gain Y/Y
|
| Oct 30 |
AbbVie lifts outlook again on immunology demand; dividend raised
|
| Oct 30 |
AbbVie raises profit forecast as CEO cites business "momentum"
|
| Oct 30 |
Earnings Snapshot: AbbVie FY profit guidance beats forecast, Q3 Humira revenue lags
|
| Oct 30 |
AbbVie raises 2024 profit forecast on strong sales of key drugs Skyrizi, Rinvoq
|
| Oct 30 |
AbbVie: Q3 Earnings Snapshot
|
| Oct 30 |
AbbVie lifts dividend by 5.8% to $1.64/share
|
| Oct 30 |
AbbVie Non-GAAP EPS of $3.00 beats by $0.08, revenue of $14.46B beats by $180M
|
| Oct 30 |
AbbVie Reports Third-Quarter 2024 Financial Results
|
| Oct 30 |
3 Dividend Growth Stocks to Buy and Never Sell
|
